HeartBeam has announced a strategic alliance agreement (SAA) with global tech giant Samsung.
The alliance, announced today, builds upon an existing SAA between Samsung and Livmor, whose assets HeartBeam acquired earlier this year.
Livmor created the FDA-cleared wearable Halo atrial fibrillation detection system — an FDA-cleared, Samsung-Galaxy-watch-based arrhythmia detection tool. Meanwhile, HeartBeam recently secured a pivotal patent related to artificial intelligence capabilities for its AIMIGo system — a personal, portable vector electrocardiogram (VECG) system. Also, this month, HeartBeam submitted AIMIGo for FDA 510(k) clearance.
This collaborative venture between HeartBeam and Samsung will explore opportunities to leverage HeartBeam’s proprietary technology and expertise in cardiac symptom assessment and monitoring. The two companies think their technologies could boost the standard of cardiac diagnostic capabilities.
HeartBeam’s CEO and founder Branislav Vajdic said the integration of Halo with the AIMIGo telehealth platform could significantly expand product capabilities beyond existing options for at-home cardiac patients.
The collaboration also promises potential engagements with the Department of Veterans Affairs through the Accelerating VA Innovation and Learning (AVAIL) program. HeartBeam’s participation in the AVAIL project will extend its expertise in cardiac symptom monitoring and assessment in collaboration with Samsung to provide innovative solutions for the VA, the largest integrated healthcare system in the U.S.
The potential for AVAIL participation comes from Livmor and Samsung being official collaborators with systems integration company Longview International Technology Solutions (LTS). LTS is one of 17 companies that won spots in a potential five-year, $650 million healthcare technology research and development program for the VA.
Said Kevin Jones, senior director of Federal Healthcare Samsung Electronics America: “The potential of combining Livmor’s technology and the HeartBeam AIMIGo system holds significant promise to address major cardiac conditions for our veterans.”